Developer docs
API playgroundTry for free, no card

Search company profiles

Franklin Biolabs

Full company profile

uuid0006rhc

Namestring
Franklin Biolabs
Legal namestring
Franklin Biolabs
Websiteurl
franklinbio.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Franklin Biolabs is a privately held preclinical contract research organization headquartered in the Philadelphia area (King of Prussia), founded in 2024, that specializes in genetic medicines and biologics with a primary focus on adeno-associated virus (AAV) vector production. The company inherited manufacturing capabilities from the Penn Vector Core of the University of Pennsylvania Gene Therapy Program, giving it an established process library, serotype portfolio (including AAV1/2/5/8/9 plus more than 75 engineered serotypes), and a claimed 100% IND approval success rate since 2019. Its 150,000 sq. ft. facility houses dual production platforms (Sartorius single-use suspension bioreactors from 2L to 500L+ and iCELLis fixed-bed adherent bioreactors from 2.4 m² to 200+ m²), complemented by analytical, in vivo, and bioanalytics units, and recently earned CLIA certification for clinical-grade AAV neutralizing antibody testing.

The company's service portfolio is organized into three integrated business units: Vector | CMC | Analytics (research vector production, large-scale manufacturing, process development, and analytical testing), Preclinical | Translational (GLP toxicology, pharmacology, pharmacokinetics, and pathology), and Bioanalytics (immunogenicity, biodistribution, viral shedding). Add-on offerings include adenovirus and lentivirus production for CAR-T, oncolytic, and vaccine programs, plus CMC consulting. Franklin Biolabs has supported more than 1,000 clients across 30+ countries, 30 clinical candidates over the past five years, 50+ GMP manufacturing runs, and 3,000+ animal studies, with a reported 18–24 month timeline from candidate to IND.

Revenue is generated through project-based preclinical contract research services sold directly to global biotech, pharmaceutical, and academic institutions via enterprise field sales, supplemented by an online research vector ordering portal (VPM Portal) for mid-market and academic buyers. The company pursues a concierge, scientifically-engaged go-to-market approach, supported by industry conference presence (notably ASGCT), PR-led partnership announcements, and content marketing. Recent commercial moves include strategic alliances with Nordic Cell Therapy Group (cell therapy expansion, April 2026) and RareMoon Consulting (regulatory consulting bundling, May 2026). No ownership, funding, headcount, or revenue disclosures are available.

Short descriptiontext

Franklin Biolabs is a US preclinical CRO specializing in AAV vector production, process development, GLP toxicology, and bioanalytics for genetic medicines, serving global biotech, pharma, and academic gene therapy developers with a 150,000 sq. ft. Philadelphia-area facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKing Of Prussia, United States
HQ citystring
King Of Prussia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, AAV vector manufacturing, gene therapy contract research, biologics process development, GLP toxicology studies
Industry4 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Preclinical Contract Research Services (Gene Therapy / Cell Therapy CRO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical Contract Research Services
TypeProfessional Services
Description

Franklin Biolabs generates revenue through providing comprehensive preclinical CRO services including research vector production, process development, large-scale manufacturing, analytics, and preclinical studies (toxicology, pharmacology, biodistribution) on a project-based contract basis. Services span from early discovery support through IND-enabling studies.

franklinbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Franklin Biolabs is a fully integrated preclinical contract research organization (CRO) that provides AAV vector manufacturing, process development, analytical testing, GLP toxicology/in vivo studies, bioanalytics, and CMC consulting for cell and gene therapy developers. Its services span from early discovery research vector production through IND-enabling studies, supported by dual suspension and adherent production platforms and a CLIA-certified AAV NAb testing capability.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% IND approval success rate since 2019
+3 more records
Product overview1 text field

Franklin Biolabs is a fully integrated preclinical Contract Research Organization (CRO) specializing in genetic medicines and biologics. The company operates three interconnected business units: (1) Vector | CMC | Analytics encompassing research vector production, large-scale AAV manufacturing, process development, and analytical testing; (2) Preclinical | Translational Services including GLP toxicology, in vivo studies, and pathology; and (3) Bioanalytics covering immunogenicity, biodistribution, and viral shedding. The company has acquired certain vector manufacturing capabilities from the Penn Vector Core and offers integrated CMC consulting services. All services are designed to support clients from discovery through IND submission, with a reported 100% IND approval success rate since 2019.

Product and service9 records
1Research Vector Production
CategoryVector Manufacturing
Description

AAV research vector packaging and production services for preclinical studies, supporting gene therapy development from early discovery through IND submissions. Includes wild type and engineered serotypes, novel capsid packaging, and custom vector design for biotech, pharma, and academic clients.

2Large-Scale AAV Manufacturing
CategoryVector Manufacturing
Description

Scalable AAV vector manufacturing at clinical scale using suspension (Sartorius single-use bioreactors, 2L to 500L+) and adherent (iCELLis fixed-bed bioreactors, 2.4m² to 200+m²) production platforms to support IND-enabling studies and GMP-ready material production.

3Process Development
CategoryCMC Services
Description

Upstream and downstream process development services for AAV vectors, including transfection parameter optimization, media selection, feed strategy, scale-up confirmation, and platform-based or client-specific purification methods.

4Analytics
CategoryAnalytical Services
Description

Comprehensive analytical testing services for genetic medicines, including next-generation sequencing, particle characterization, titer assays, compendial assays, excipient analysis, mass spectrometry, cell-based potency assays, residuals testing, and custom assay development.

5Preclinical / Translational Services
CategoryPreclinical / Translational Research
Description

In vivo preclinical and translational studies including pharmacology, efficacy, pharmacokinetics, and GLP toxicology studies with QA oversight, histopathology, image analysis, and safety assessments for cell and gene therapies.

6Bioanalytics
CategoryBioanalytical Services
Description

Bioanalytical services including immunogenicity assessment, biodistribution studies, viral shedding analysis, and biomarker characterization for advanced therapies from preclinical through clinical stages.

7Immunogenicity Services
CategoryBioanalytical Services
Description

Assessment services for antibodies to AAV vectors that may reduce efficacy of gene therapies, with evaluation throughout preclinical and clinical stages, including CLIA-certified AAV neutralizing antibody testing.

8Adenovirus and Lentivirus Production
CategoryVector Manufacturing
Description

Expanded viral vector production services for adenovirus and lentivirus, supporting CAR-T applications, oncolytic programs, and vaccine development in addition to AAV vectors.

9CMC Consulting Services
CategoryConsulting Services
Description

End-to-end Chemistry, Manufacturing & Controls (CMC) consulting solutions for advanced therapies, including manufacturing and analytical foundation development, phase-appropriate processes, analytical strategies, and development roadmaps to support IND readiness.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-07
Description

Franklin Biolabs and RareMoon Consulting announced a strategic partnership to offer integrated consulting packages supporting preclinical-to-clinical development transitions. The collaboration aims to help sponsors reduce development risk, prevent delays, and accelerate timelines by designing regulatory-aligned development programs. Both companies will attend the ASGCT Annual Meeting in Boston, Massachusetts from May 12-14, 2026. RareMoon Consulting brings regulatory services expertise focused on orphan drugs and advanced therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Franklin Biolabs and Nordic Cell Therapy Group announced a strategic alliance to accelerate cell therapy development. This partnership expands Franklin Biolabs' capabilities in the cell therapy space, combining their preclinical expertise with Nordic Cell Therapy Group's specialized offerings.

3Penn Vector Core (University of Pennsylvania)
Strategic tierCoreTypeTechnology or Integration
Description

Certain vector manufacturing capabilities previously provided by the Penn Vector Core of the Gene Therapy Program at the University of Pennsylvania have been acquired by Franklin Biolabs. This transfer brought established manufacturing processes, expertise, and established customer relationships to Franklin Biolabs.

franklinbio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Yposkesi
TypeDirect peer
Description

Yposkesi is a European-based AAV and gene therapy CDMO offering process development, GMP manufacturing, and analytical services. It is a comparable specialized competitor serving a similar biotech and academic sponsor base.

TypeBroad incumbent
Description

Charles River Laboratories is a global preclinical CRO with extensive safety assessment, toxicology, and biologics capabilities, including viral vector work via the Cobra acquisition. It is a broad incumbent serving overlapping biotech and pharma customers.

TypeBroad incumbent
Description

WuXi AppTec's Advanced Therapies unit offers viral vector and cell therapy manufacturing services globally. It is a broad incumbent with overlapping AAV and gene therapy CRO/CDMO capabilities competing for biotech sponsor business.

TypeOthers
Description

Lonza is a global biopharmaceutical CDMO with expanding cell and gene therapy manufacturing capacity. It competes with Franklin Biolabs across AAV, cell therapy, and biologics services, though at much greater scale.

5Vineti
TypeEmerging player
Description

Vineti provides cell and gene therapy orchestration and supply chain software/platforms. While not a direct manufacturing peer, it serves the same advanced therapy sponsors and is adjacent in the gene therapy development workflow.

TypeDirect peer
Description

Forge Biologics is a dedicated AAV and gene therapy CDMO offering end-to-end development, manufacturing, and analytical services. It is the closest direct competitor to Franklin Biolabs in AAV-focused contract services.

7Cobra Biologics (Charles River)
TypeDirect peer
Description

Cobra Biologics, now part of Charles River Laboratories, provides viral vector and plasmid DNA manufacturing services for gene therapy and vaccine clients. It directly overlaps with Franklin Biolabs' AAV and lentivirus vector production offerings.

TypeDirect peer
Description

Andelyn Biosciences is an AAV and gene therapy-focused CDMO spun out of Nationwide Children's Hospital. It competes directly with Franklin Biolabs in preclinical and clinical-stage AAV manufacturing for academic and biotech sponsors.

TypeBroad incumbent
Description

Catalent is one of the largest global CDMOs with significant AAV and gene therapy capabilities following the Paragon acquisition. It is a broad incumbent offering overlapping preclinical and commercial manufacturing services to similar biotech and pharma customers.

TypeBroad incumbent
Description

Thermo Fisher Scientific offers viral vector manufacturing and related analytical services through its Pharma Services division. It is a broad incumbent competing with Franklin Biolabs for gene therapy CRO/CDMO business at larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Franklin Biolabs

Preclinical Contract Research Services (Gene Therapy / Cell Therapy CRO)franklinbio.com

Franklin Biolabs is a US preclinical CRO specializing in AAV vector production, process development, GLP toxicology, and bioanalytics for genetic medicines, serving global biotech, pharma, and academic gene therapy developers with a 150,000 sq. ft. Philadelphia-area facility.

What Franklin Biolabs does

Franklin Biolabs is a privately held preclinical contract research organization headquartered in the Philadelphia area (King of Prussia), founded in 2024, that specializes in genetic medicines and biologics with a primary focus on adeno-associated virus (AAV) vector production. The company inherited manufacturing capabilities from the Penn Vector Core of the University of Pennsylvania Gene Therapy Program, giving it an established process library, serotype portfolio (including AAV1/2/5/8/9 plus more than 75 engineered serotypes), and a claimed 100% IND approval success rate since 2019. Its 150,000 sq. ft. facility houses dual production platforms (Sartorius single-use suspension bioreactors from 2L to 500L+ and iCELLis fixed-bed adherent bioreactors from 2.4 m² to 200+ m²), complemented by analytical, in vivo, and bioanalytics units, and recently earned CLIA certification for clinical-grade AAV neutralizing antibody testing.

The company's service portfolio is organized into three integrated business units: Vector | CMC | Analytics (research vector production, large-scale manufacturing, process development, and analytical testing), Preclinical | Translational (GLP toxicology, pharmacology, pharmacokinetics, and pathology), and Bioanalytics (immunogenicity, biodistribution, viral shedding). Add-on offerings include adenovirus and lentivirus production for CAR-T, oncolytic, and vaccine programs, plus CMC consulting. Franklin Biolabs has supported more than 1,000 clients across 30+ countries, 30 clinical candidates over the past five years, 50+ GMP manufacturing runs, and 3,000+ animal studies, with a reported 18–24 month timeline from candidate to IND.

Revenue is generated through project-based preclinical contract research services sold directly to global biotech, pharmaceutical, and academic institutions via enterprise field sales, supplemented by an online research vector ordering portal (VPM Portal) for mid-market and academic buyers. The company pursues a concierge, scientifically-engaged go-to-market approach, supported by industry conference presence (notably ASGCT), PR-led partnership announcements, and content marketing. Recent commercial moves include strategic alliances with Nordic Cell Therapy Group (cell therapy expansion, April 2026) and RareMoon Consulting (regulatory consulting bundling, May 2026). No ownership, funding, headcount, or revenue disclosures are available.

Franklin Biolabs firmographics

Firmographics
Name
Franklin Biolabs
Legal name
Franklin Biolabs
Website
https://franklinbio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
51–100 employees
Short description
Franklin Biolabs is a US preclinical CRO specializing in AAV vector production, process development, GLP toxicology, and bioanalytics for genetic medicines, serving global biotech, pharma, and academic gene therapy developers with a 150,000 sq. ft. Philadelphia-area facility.
Ownership category
akta.pro rank

Franklin Biolabs industry classification

Industry
Product category
Preclinical Contract Research Services (Gene Therapy / Cell Therapy CRO)
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs

Keywords

  • Preclinical CRO services
  • AAV vector manufacturing
  • Gene therapy contract research
  • Biologics process development
  • GLP toxicology studies

Where Franklin Biolabs is headquartered

Location

Headquarters

HQ city
King Of Prussia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Franklin Biolabs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Preclinical Contract Research Services: Franklin Biolabs generates revenue through providing comprehensive preclinical CRO services including research vector production, process development, large-scale manufacturing, analytics, and preclinical studies (toxicology, pharmacology, biodistribution) on a project-based contract basis. Services span from early discovery support through IND-enabling studies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Franklin Biolabs product offering

Product offering

Core offering

Franklin Biolabs is a fully integrated preclinical contract research organization (CRO) that provides AAV vector manufacturing, process development, analytical testing, GLP toxicology/in vivo studies, bioanalytics, and CMC consulting for cell and gene therapy developers. Its services span from early discovery research vector production through IND-enabling studies, supported by dual suspension and adherent production platforms and a CLIA-certified AAV NAb testing capability.

Product overview

Franklin Biolabs is a fully integrated preclinical Contract Research Organization (CRO) specializing in genetic medicines and biologics. The company operates three interconnected business units: (1) Vector | CMC | Analytics encompassing research vector production, large-scale AAV manufacturing, process development, and analytical testing; (2) Preclinical | Translational Services including GLP toxicology, in vivo studies, and pathology; and (3) Bioanalytics covering immunogenicity, biodistribution, and viral shedding. The company has acquired certain vector manufacturing capabilities from the Penn Vector Core and offers integrated CMC consulting services. All services are designed to support clients from discovery through IND submission, with a reported 100% IND approval success rate since 2019.

Differentiator

Problem solved

Functional benefit

Products and services

  • Research Vector Production AAV research vector packaging and production services for preclinical studies, supporting gene therapy development from early discovery through IND submissions. Includes wild type and engineered serotypes, novel capsid packaging, and custom vector design for biotech, pharma, and academic clients.
  • Large-Scale AAV Manufacturing Scalable AAV vector manufacturing at clinical scale using suspension (Sartorius single-use bioreactors, 2L to 500L+) and adherent (iCELLis fixed-bed bioreactors, 2.4m² to 200+m²) production platforms to support IND-enabling studies and GMP-ready material production.
  • Process Development Upstream and downstream process development services for AAV vectors, including transfection parameter optimization, media selection, feed strategy, scale-up confirmation, and platform-based or client-specific purification methods.
  • Analytics Comprehensive analytical testing services for genetic medicines, including next-generation sequencing, particle characterization, titer assays, compendial assays, excipient analysis, mass spectrometry, cell-based potency assays, residuals testing, and custom assay development.
  • Preclinical / Translational Services In vivo preclinical and translational studies including pharmacology, efficacy, pharmacokinetics, and GLP toxicology studies with QA oversight, histopathology, image analysis, and safety assessments for cell and gene therapies.
  • Bioanalytics Bioanalytical services including immunogenicity assessment, biodistribution studies, viral shedding analysis, and biomarker characterization for advanced therapies from preclinical through clinical stages.
  • Immunogenicity Services Assessment services for antibodies to AAV vectors that may reduce efficacy of gene therapies, with evaluation throughout preclinical and clinical stages, including CLIA-certified AAV neutralizing antibody testing.
  • Adenovirus and Lentivirus Production Expanded viral vector production services for adenovirus and lentivirus, supporting CAR-T applications, oncolytic programs, and vaccine development in addition to AAV vectors.
  • CMC Consulting Services End-to-end Chemistry, Manufacturing & Controls (CMC) consulting solutions for advanced therapies, including manufacturing and analytical foundation development, phase-appropriate processes, analytical strategies, and development roadmaps to support IND readiness.

Quantifiable outcome

  • 100% IND approval success rate since 2019
  • +3 more outcomes

Companies that use Franklin Biolabs

Customer profile

Segments2 records

Ideal customer profiles2 records

Franklin Biolabs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Franklin Biolabs partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • RareMoon ConsultingcoreStrategic or Co-development Partner · 7 May 2026Franklin Biolabs and RareMoon Consulting announced a strategic partnership to offer integrated consulting packages supporting preclinical-to-clinical development transitions. The collaboration aims to help sponsors reduce development risk, prevent delays, and accelerate timelines by designing regulatory-aligned development programs. Both companies will attend the ASGCT Annual Meeting in Boston, Massachusetts from May 12-14, 2026. RareMoon Consulting brings regulatory services expertise focused on orphan drugs and advanced therapies.
  • Nordic Cell Therapy GroupcoreStrategic or Co-development Partner · 1 April 2026Franklin Biolabs and Nordic Cell Therapy Group announced a strategic alliance to accelerate cell therapy development. This partnership expands Franklin Biolabs' capabilities in the cell therapy space, combining their preclinical expertise with Nordic Cell Therapy Group's specialized offerings.
  • Penn Vector Core (University of Pennsylvania)coreTechnology or IntegrationCertain vector manufacturing capabilities previously provided by the Penn Vector Core of the Gene Therapy Program at the University of Pennsylvania have been acquired by Franklin Biolabs. This transfer brought established manufacturing processes, expertise, and established customer relationships to Franklin Biolabs.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Franklin Biolabs competitors and assessment

Company assessment

Direct peers

  • Yposkesi: Yposkesi is a European-based AAV and gene therapy CDMO offering process development, GMP manufacturing, and analytical services. It is a comparable specialized competitor serving a similar biotech and academic sponsor base.
  • Forge Biologics: Forge Biologics is a dedicated AAV and gene therapy CDMO offering end-to-end development, manufacturing, and analytical services. It is the closest direct competitor to Franklin Biolabs in AAV-focused contract services.
  • Cobra Biologics (Charles River): Cobra Biologics, now part of Charles River Laboratories, provides viral vector and plasmid DNA manufacturing services for gene therapy and vaccine clients. It directly overlaps with Franklin Biolabs' AAV and lentivirus vector production offerings.
  • Andelyn Biosciences: Andelyn Biosciences is an AAV and gene therapy-focused CDMO spun out of Nationwide Children's Hospital. It competes directly with Franklin Biolabs in preclinical and clinical-stage AAV manufacturing for academic and biotech sponsors.

Broad incumbents

  • Charles River Laboratories: Charles River Laboratories is a global preclinical CRO with extensive safety assessment, toxicology, and biologics capabilities, including viral vector work via the Cobra acquisition. It is a broad incumbent serving overlapping biotech and pharma customers.
  • WuXi Advanced Therapies: WuXi AppTec's Advanced Therapies unit offers viral vector and cell therapy manufacturing services globally. It is a broad incumbent with overlapping AAV and gene therapy CRO/CDMO capabilities competing for biotech sponsor business.
  • Catalent (Novo Holdings): Catalent is one of the largest global CDMOs with significant AAV and gene therapy capabilities following the Paragon acquisition. It is a broad incumbent offering overlapping preclinical and commercial manufacturing services to similar biotech and pharma customers.
  • Thermo Fisher Viral Vector Services: Thermo Fisher Scientific offers viral vector manufacturing and related analytical services through its Pharma Services division. It is a broad incumbent competing with Franklin Biolabs for gene therapy CRO/CDMO business at larger scale.

Others

  • Lonza: Lonza is a global biopharmaceutical CDMO with expanding cell and gene therapy manufacturing capacity. It competes with Franklin Biolabs across AAV, cell therapy, and biologics services, though at much greater scale.

Emerging players

  • Vineti: Vineti provides cell and gene therapy orchestration and supply chain software/platforms. While not a direct manufacturing peer, it serves the same advanced therapy sponsors and is adjacent in the gene therapy development workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Franklin Biolabs social profiles

Digital presence

Franklin Biolabs compliance and trust

Trust signal

Compliance1 record

Franklin Biolabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Franklin Biolabs leadership team

Management profile

Number of profiles

Profiles1 record

Franklin Biolabs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Franklin Biolabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Franklin Biolabs

What does Franklin Biolabs do?

Franklin Biolabs is a fully integrated preclinical contract research organization (CRO) that provides AAV vector manufacturing, process development, analytical testing, GLP toxicology/in vivo studies, bioanalytics, and CMC consulting for cell and gene therapy developers. Its services span from early discovery research vector production through IND-enabling studies, supported by dual suspension and adherent production platforms and a CLIA-certified AAV NAb testing capability.

Is Franklin Biolabs a public or private company?

Franklin Biolabs is a private company. It is classified as unknown and is currently operating.

When was Franklin Biolabs founded?

Franklin Biolabs was founded in 2024. It employs 51 to 100 people.

Where is Franklin Biolabs based?

Franklin Biolabs is headquartered in King Of Prussia, United States, in the North America region.

How does Franklin Biolabs make money?

One revenue line is on record: preclinical Contract Research Services.

Who are Franklin Biolabs's main competitors?

Direct peers on record are Yposkesi, Forge Biologics, Cobra Biologics (Charles River) and Andelyn Biosciences. Broad incumbents are Charles River Laboratories, WuXi Advanced Therapies, Catalent (Novo Holdings) and Thermo Fisher Viral Vector Services. Lonza is listed as an others. Vineti is listed as an emerging player.

Does Franklin Biolabs have an API?

No public API is recorded for Franklin Biolabs.

What industry is Franklin Biolabs in?

Franklin Biolabs's product category is Preclinical Contract Research Services (Gene Therapy / Cell Therapy CRO). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournFranklin Biolabs and RareMoon Consulting announce a Strategic Partnership to integrate Preclinical Development with Regulatory ExpertiseFranklin Biolabs, a preclinical contract research organization specializing in genetic medicine and biologics, and RareMoon Consulting, a regulatory services firm focused on orphan drugs and advanced therapies, have announced a strategic partnership to offer joint consulting packages for preclinical-to-clinical transitions. The collaboration aims to help sponsors design development programs that align with regulatory expectations, reduce development risk, prevent delays, and accelerate timelines by avoiding unnecessary studies. Both companies will discuss the partnership at the ASGCT Annual Meeting in Boston, May 12–14.PR NewswireFranklin Biolabs and RareMoon Consulting announce a Strategic Partnership to integrate Preclinical Development with Regulatory ExpertiseFranklin Biolabs, a preclinical contract research organization specializing in genetic medicines and biologics, and RareMoon Consulting, a regulatory services firm focused on orphan drugs and advanced therapies, have announced a strategic partnership to offer integrated consulting packages supporting preclinical-to-clinical development transitions. The collaboration aims to help sponsors reduce development risk, prevent delays, and accelerate timelines by designing regulatory-aligned development programs that focus on meeting regulatory expectations. Both companies will attend the ASGCT Annual Meeting in Boston, Massachusetts from May 12–14, 2026.GenengnewsAccelerating GMP Quality Control with Mass Photometry from Development to ReleaseFranklin Biolabs is promoting a webinar led by Associate Director Ray Zhang, PhD, on accelerating GMP quality control using mass photometry for biologics and gene therapies. The session details how this rapid, label-free technique can streamline analytical workflows, reduce operational burdens, and improve productivity compared to traditional methods like AUC. The event includes technical discussions on method robustness and a case study demonstrating real-world CDMO QC applications.The Daily PennsylvanianPenn Gene Therapy Program and director to depart University, transfer to external companiesJames Wilson, director of the University of Pennsylvania's Gene Therapy Program, will depart Penn with the program's functions and assets transferred to two new for-profit companies: GEMMA Biotherapeutics and Franklin Biolabs. Penn's Board of Trustees executive committee approved the spinout on July 31, with the transition effective October 1, resulting in approximately 220 employees receiving offers to work at the new companies while about 25 will be laid off. Founded by Wilson in 1993, GTP is being transitioned to the biotech industry to scale gene therapy activities, with Wilson serving as CEO of GEMMA Biotherapeutics and board chair of Franklin Biolabs.PR NewswireTo Further Advance Gene Therapy Research, Industry Pioneer Jim Wilson is Forming Two Independent Companies Dedicated to Genetic MedicineJames Wilson, director of Penn's Gene Therapy Program, will found GEMMA Biotherapeutics and Franklin Biolabs, transitioning GTP functions to the new entities. He will step down as GTP director to focus on the companies, which aim to accelerate gene therapy research and access. The companies will operate from the Philadelphia area with an international network.